Minneapolis Heart Institute Foundation
Trial Pipeline
DESIFOR-EXPAND (MHIF)
NCT06804980
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
NCT05305911
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
NCT07131631
Progress Complication
NCT05100940
Progress Bifurcation Global Registry
NCT05100992
Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
NCT04077762
Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions
NCT05187351
Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin
NCT00842374
Bone Marrow Stem Cell Infusion Following a Heart Attack
NCT00268307
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 28 |
| Phase 4 | 1 |
What the Pipeline for Minneapolis Heart Institute Foundation Shows
According to the ClinicalTrials.gov registry, Minneapolis Heart Institute Foundation is linked to 67 US clinical trials across every stage of research activity. Of those, 64 studies are currently recruiting — about 96% of the sponsor's indexed portfolio — and 2 are already marked complete, representing roughly 3% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Minneapolis Heart Institute Foundation reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 29 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Minneapolis Heart Institute Foundation is Coronary Artery Disease with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.